An important part of the pharma sector, clinical trials aid the drug discovery process and other medical R&D activities. Finding the most efficient way to manage and analyze the data from these studies presents a significant challenge for the industry. Just as crucially, companies often fail to ensure that clinical trial patients have proper privacy protection.
The privacy issue partly stems from the fact that conducting clinical trials currently involves a lot of intermediaries. The clinical trial data is often collected by companies whose main business is to sell that data to interested parties. The problem arises, when a buyer decides to resell the data to another company, infringing on patient privacy and failing to give the patient a cut from the resale.
Companies are now trying to solve these challenges with the help of blockchain. Nebula Genomics, a company based in Boston, Massachusetts, is working on utilizing the technology to help improve genome sequencing. The company is building a genetic database aimed at eliminating unnecessary middlemen and helping patients to safely sell their encrypted genetic data.
Another company currently working in this field is Encrypgen. The Florida-based firm has developed a blockchain-based platform that facilitates genetic data sharing, storage, selling and buying.
At Chainsus, we’ve had the opportunity to work on a similar project in this field.